drugset

drugset / Trial / NCT01754766

AGN-229666 for the Treatment of Allergic Conjunctivitis

NCT01754766 ↗

Phase 2 Completed 90 enrolled Allergan

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic conjunctivitis.

Timeline

Start: 2012-10
Primary completion: 2013-01
Completion: 2013-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AGN-229666	Unknown	—	Topical

Indications